Infinity Pharmaceuticals Inc. (INFI) President Lawrence E. Bloch Acquires 500,000 Shares
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) President Lawrence E. Bloch bought 500,000 shares of the company’s stock in a transaction on Wednesday, December 6th. The stock was purchased at an average price of $1.81 per share, with a total value of $905,000.00. Following the completion of the transaction, the president now directly owns 580,944 shares of the company’s stock, valued at approximately $1,051,508.64. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ INFI) traded down $0.09 during mid-day trading on Thursday, hitting $1.71. The stock had a trading volume of 5,042,700 shares, compared to its average volume of 1,347,128. Infinity Pharmaceuticals Inc. has a 12 month low of $0.93 and a 12 month high of $3.84.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million during the quarter, compared to analyst estimates of $14.70 million. During the same period in the previous year, the company posted ($0.39) EPS. sell-side analysts expect that Infinity Pharmaceuticals Inc. will post -0.93 EPS for the current year.
Several equities analysts have commented on the company. ValuEngine upgraded Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 12th. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Wells Fargo & Company upgraded Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th.
COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/07/infinity-pharmaceuticals-inc-infi-president-lawrence-e-bloch-acquires-500000-shares.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.